United States Últimas notícias

Replimune (NASDAQ:REPL) announced that the U.S. Food and Drug Administration has accepted for review the company’s resubmitted Biologics License Application for RP1 (vusolimogene oderparepvec) in combination with nivolumab for the treatment of advanced melanoma.

Quantum Cyber (NASDAQ:QUCY) announced that its Board of Directors has approved engaging investment banks to pursue the acquisition of an equity stake in SpaceX (NASDAQ:SPCX).

RTX (NYSE:RTX) announced that its Raytheon business has been awarded a $1.1 billion contract by the U.S. Navy to produce AIM-9X Block II missiles, along with related hardware and software.

Cineverse (NASDAQ:CNVS) reported fourth quarter fiscal 2026 revenue of $26 million, an increase of 67% from the prior-year period.

The global economy will see $1 trillion of losses per year by 2050 if we don't adapt to changing climate patterns says Sarah Kapnick, Global Head of Climate Advisory at JPMorgan. She sees this leading to a 'structural investment trend' which will see more investment in the power grid and energy transition, especially geothermal and nuclear energy. She spoke to Bloomberg's Lizzy Burden on "The Pulse."

PowerBank (NASDAQ:PBK) announced that its US subsidiary, Abundant Solar Power, has been awarded a contract by the United States Department of Defense and the Department of the Army to construct a photovoltaic array, electric vehicle chargers, and associated infrastructure at the Armed Forces Reserve Center in Farmingdale, New York.

Incyte (NASDAQ:INCY) announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has issued a positive opinion recommending approval of Opzelura (ruxolitinib) cream for the treatment of moderate atopic dermatitis in adult patients for whom topical corticosteroids and topical calcineurin inhibitors are inadequate or inappropriate.

Lilly (NYSE:LLY) announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has adopted a positive opinion recommending marketing authorization for Jaypirca (pirtobrutinib) in adults with chronic lymphocytic leukemia (CLL).

Axsome Therapeutics (NASDAQ:AXSM) announced that the first patient has been dosed in the FOCUS-3 Phase 3 trial of solriamfetol for the treatment of attention deficit hyperactivity disorder (ADHD) in adolescents.

Cameron Dawson, CIO at NewEdge Wealth, says the "huge surge in leverage" seen across markets "in order to chase the rally" is beginning to contribute to volatility.

Fortrea (NASDAQ:FTRE) appointed Jason Knoblauch as Chief Financial Officer, effective July 6, 2026.

Beyond Air (NASDAQ:XAIR) reported fiscal 2026 revenue of $7.7 million, an increase of 107% year over year.